STOCKS TELEGRAPH

Tag: LPCN

  • Lipocine Inc. (LPCN) stock Collapses After Hours. Any Reasons?

    Lipocine Inc. (LPCN) stock Collapses After Hours. Any Reasons?

    On January 14, Lipocine Inc. (LPCN) stock collapsed in the after-hours to lose 9.49% at 29.36K shares. No news from the company seems to be responsible for the downtrend in the stock.

    During the regular session, LPCN stock added 1.59% at its close of $0.9956 on Friday. Soon the stock saw a reversal as it entered the after-hours session. LPCN stock lost $0.09 in the after-hours to reach $0.9011.

    More about LPCN and its Movement

    The clinical-stage biopharmaceutical company, Lipocine Inc. was founded in 2011. Currently, the company’s 88.29 million outstanding shares trade at a market capitalization of $87.9 million. Moreover, the stock has subtracted 3.34% in the past five days and 8.66% last month. Currently, the stock stands at a year-to-date gain of a minuscule 0.45% while it lost 38.54% last year.

    On Friday, the stock traded in the green during the regular session. While there was no news from the company, LPCN entered the red in the after-hours. Hence, the stock suffered a loss of 9.49% in the after-market session on Friday.

    Phase 2 Study of LPCN 1148

    Recently, the company initiated the Phase 2 proof-of-concept clinical study of LPCN 1148 for the management of liver cirrhosis. Further, it is a multi-center, randomized, placebo-controlled 52-week study in sarcopenic cirrhotic patients who are on the liver transplant list.

    Currently, decompensated liver cirrhosis has only one cure of liver transplant, which is a very expensive and time-consuming process.

    The study’s endpoints include the following:  Firstly, the primary endpoint of the study changes in Skeletal Muscle Index (SMI) from baseline through computed tomography against placebo at week 24. Secondly, measures of frailty, change in waitlist events, myoteatosis, rate of hospital admissions, all-cause mortality, and decompensation events are some of the key secondary endpoints.

    On December 22, 2021, LPCN announced the dosing of the first patient in the Phase 2 study. The company expects to provide the primary endpoint topline results from the study in the second half of 2022.

    LPCN 1148 is the company’s novel prodrug with the potential of improving liver and muscle function.

    Financial Highlights

    The company declared its financial results for the third quarter of 2021, on November 10.

    In the third quarter of 2021, LPCN had a net loss of $3.1 million ($0.03/share) against $4.3 million ($0.07/share) in Q3 of 2020.

    Furthermore, the company ended the quarter with unrestricted cash, cash equivalents, and marketable securities of $38.7 million. As part of licensing agreement with Antares Pharma, the company also received an $11.0 million upfront license fee after the end of the quarter.

  • Lipocine Inc. (LPCN) stock surged in the after-hours on Wednesday after a recent announcement

    Lipocine Inc. (LPCN) shares surged 11.63% in after-hours on Wednesday, July 14, 2021, and closed the trading at $1.44 per share. Earlier in the morning session on Wednesday, LPCN’s stock lost 2.27% to close Wednesday’s session at $1.29. LPCN shares have risen 4.88% over the last 12 months, and they have moved down 4.44% in the past week. Over the past three months, the stock has lost 12.24%, while over the past six months, it has shed 20.86%.

    Let’s have a brief look at its recent developments.

    Settlement With Clarus Therapeutics

    On July 14, 2021, Lipocine Inc entered into a global settlement and license agreement with Clarus Therapeutics Inc (Clarus) to resolve all outstanding claims in the ongoing intellectual property battle between the two companies as well as the ongoing interference proceeding between the two companies.

    Both companies agreed to dismiss the Lipocine Inc. v Clarus Therapeutics, Inc., No 19-cv-622 (WCB) litigation presently pending in the U.S. District Court for the District of Delaware and interference proceedings captioned Clarus Therapeutics, Inc. v. Lipocine Inc., Interference No. 106,128 presently pending in the U.S. Patent and Trademark. The terms of the settlement remain confidential.

    Participation in the recent health and investor conferences

    Lipocine Inc recently participated virtually at Ladenburg Thalmann Healthcare Conference, which held on July 13-14, 2021.

    Earlier, the company took part in The International Liver Congress™ in 2021, the annual meeting of the European Association for the Study of the Liver (EASL), Digital Event, which held on June 23-26, 2021.

    Lipocine was present at Raymond James Human Health Innovation Conference which held on June 21-23, 2021, and at Lytham Partners Summer 2021 Investor Conference which held on June 14-16, 2021.

    LPCN 1154 IND application cleared by FDA

    On June 14, 2021, the U.S. Food and Drug Administration (FDA) cleared Lipocine’s Investigational New Drug Application to initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154, an oral neuro-steroid product candidate, for the treatment of postpartum depression in adults.

    Clarus Therapeutics won Patent Infringement Case against Lipocine

     

    On May 25, 2021, The U.S. District Court for the District of Delaware granted Clarus Therapeutics’ motion for summary judgment against remaining patents in a patent infringement case brought by Lipocine Inc regarding Clarus’s oral testosterone replacement product, Jatenzo.

    The statement gave Clarus an unequivocal win, Judge Bryson found all of the asserted Lipocine patents claims invalid.

    Conclusion

    The latest settlement with Clarus Therapeutics was the reason behind its gains in the after-hours on Wednesday because investors always take such news as a positive development. We can see LPCN to surge in the coming days.

  • Early Morning Vibes: 4 Hot Stocks You Might Consider For Thursday

    Early Morning Vibes: 4 Hot Stocks You Might Consider For Thursday

    The American stock markets plummeted again yesterday. The S&P 500 fell 1.31% and the Nasdaq even lost 2.70% and closed at 12,997 points.  On balance, it is not too bad, because the Nasdaq is still stabilizing just above the support zone at 12,985 points. However, it is increasingly likely that this support will break. A small head & shoulder pattern appears to have formed on the graph. If the neckline / support line is broken, we get a technical price target of approximately 12,000 points. So there seems to be even more decline in the pipeline.

    Just like the past few weeks, tech was again the most bitten dog. The turmoil in the bond markets continues to affect the equity market. The fee on 10-year US Treasury notes increased 6 basis points to 1.46%. Because technology stocks are relatively expensive, they are particularly affected. A higher interest rate usually results in lower profit expectations. Individual losses rose sharply. Amazon lost more than 3%, Netflix fell by more than 5% and Baidu even saw 9.23% of stock market value evaporate. Remarkably, there was still room for speculation; GameStop was raised 5% and Uber was also up 2.67%.

    Investors were also not satisfied with the job report that pay slip processor ADP published. The figures showed that only 117,000 new jobs were created in the month of February. Analysts had anticipated an increase of 175,000 jobs. This may indicate that the recovery of the US labor market is slower than expected. On Friday, the US government will release the official figures.

    Today Top Movers

    Allied Esports Entertainment Inc. (AESE) stock soared 44.0% to $3.6 in the pre-market trading.

    Lipocine Inc. (NASDAQ: LPCN) shares are trading up 25.87% at $1.8 at the time of writing. The company will present clinical data for lead candidate TLANDO™ at the ENDO 2021 Conference.

    Super League Gaming Inc. (SLGG) grew over 26.49% at $6.59 in pre-market trading today.

    Severn Bancorp Inc. (SVBI), a savings and loan holding company, rose about 21.84% at $10.21 in pre-market trading Thursday.

    Top Upgrades & Downgrades

    Jefferies turned bullish on Cummins Inc. (CMI), upgrading the stock to “Buy” and assigning a $325.0 price target, representing a potential upside of 24.07% from Wednesday’s close. 

    SITE Centers Corp. (SITC) has won the favor of KeyBanc’s equity research team. The firm upgraded the shares from Sector Weight to Overweight and moved their price target to $15.0, suggesting 16.32% additional upside for the stock. 

    Kite Realty Group Trust (KRG) received an upgrade from analysts at KeyBanc, who also set their one-year price target on the stock to $22.0. They changed their rating on KRG to Overweight from Sector Weight in a recently issued research note.

    Earlier Thursday HC Wainwright & Co. reduced its rating on KemPharm Inc. (KMPH) stock to Neutral from Buy and assigned the price target to $12.0.

    Barclays analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Banco Bilbao Vizcaya Argentaria S.A. (BBVA) has been changed to Equal-Weight from Overweight. 

    Analysts at KeyBanc downgraded Retail Properties of America Inc. (RPAI)’s stock to Sector Weight from Overweight Thursday.

    Latest Insider Activity

    Palantir Technologies Inc. (PLTR) Director Moore Alexander D. announced the sale of shares taking place on Mar 01 at $24.97 for some 12,000 shares. The total came to more than $0.3 million. 

    Tesla Inc. (TSLA) SVP Powertrain and Energy Eng. Baglino Andrew D sold on Mar 01 a total of 18,726 shares at $690.11 on average. The insider’s sale generated proceeds of almost $1.04 million. 

    Lowe’s Companies Inc. (LOW) Director BATCHELDER DAVID H declared the purchase of shares taking place on Feb 26 at $159.48 for some 6,250 shares. The transaction amount was around $1.0 million. 

    Hanesbrands Inc. (HBI) Group Pres., Global Innerwear Cavaliere Joseph W bought on Mar 01 a total of 64,209 shares at $17.98 on average. The purchase cost the insider an estimated $299,367.

    Important Earnings

    Top US earnings releases scheduled for today include SmileDirectClub Inc. (NASDAQ: SDC). It will announce its Dec 2020 financial results. The company is expected to report earnings of -$0.1 per share from revenues of $181.1M in the three-month period. 

    Analysts expect Opendoor Technologies Inc. (NASDAQ: OPEN) to report a net income (adjusted) of -$0.1 per share when the company releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $243.94M. 

    The Gap, Inc. (GPS), due to announce earnings after the market closes today, is expected to report earnings of $0.18 per share from revenues of $4.66B recently concluded three-month period.

  • Lipocine Inc. [LPCN] is a stock which investors cannot afford to ignore

    Lipocine Inc. (Nasdaq: LPCN), shares have changed -12.80% in price in a 5-day period, and -10.63% in the past three months. Shares of LPCN are up 5.15% YTD, with their twelve-month performance up 162.48%. In the last year, the lowest price was $53.15 and the highest was $138.79.

    Lipocine Inc. (Nasdaq: LPCN), is a clinical-stage biopharmaceutical company developing novel drug delivery technologies for metabolic and endocrine disorders. TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107 are in Lipocine’s clinical development pipeline. The FDA has tentatively approved TLANDO, an oral prodrug of testosterone containing testosterone undecanoate, for the treatment of men who have deficiency of endogenous testosterone, also called hypogonadism.

    WHAT HAPPENED RECENTLY

    It was announced March 3, 2021 that Lipocine Inc. (Nasdaq: LPCN), the developer of TLANDO, will present their clinical data at the ENDO 2021 Conference, which is scheduled for March 20-23, 2021. For adult males with conditions associated with a lack of endogenous testosterone, called hypogonadism, TLANDO is an oral testosterone replacement therapy product candidate.

    Meanwhile,

    An analysis of the pharmaceutical industry shows that only a small percentage of Phase I products ever make it to the market. Typically, the percentage rises to 40% in Phase II and 70% in Phase III. Thus, a drug at Phase I is clearly a riskier investment than at Phase III. Market potentials can be determined using publicly available data on patient populations and current prices per patient/year. An analysis of competitor activity will demonstrate the number of companies conducting research on the same disease, and the level of their progress. The analysts claim that as a result, all major risks in a product development are quantifiable, such as clinical and competitor risk. It is possible to calculate the net present value or its net value to the company by adding up the risks.

  • Early Morning Vibes: 4 Top Trending Stocks To Watch For Monday

    Early Morning Vibes: 4 Top Trending Stocks To Watch For Monday

    Last week indices in the United States managed to set fresh records on the price boards. Interestingly, we saw Wall Street indices initially take a dip on Friday. This dip came after the US government announced that employment declined in December. Contrary to expectations, the number of jobs fell by 140,000, while economists had expected an increase of about 50,000 jobs. The question is whether this has halted the recovery of the labor market or whether this effect is temporary due to stricter corona measures.

    In response to the bad jobs report, upcoming president Joe Biden announced that he would come up with additional stimulus measures to get the US economy through the corona crisis. The stock markets recovered towards the close and eventually, the indices closed at the highest point of the day. The S&P 500 closed with a gain of 0.55% at 3,824 points and the Nasdaq gained 1.03% at 13,202 points.

    Earnings Update

    This week the earnings season will officially start, and the American major banks will give the starting shot. Citigroup, JPMorgan Chase and Wells Fargo, among others, will open the books this Friday. On Tuesday, Just Eat Takeaway, Blackrock, and Alcoa will be the first to open the books.

    Corporate News

    Twitter’s share price closed 1.61% lower on Friday. According to Twitter, Donald Trump incites violence and Facebook and Instagram also blocked Trump’s accounts until at least until after the inauguration of Joe Biden. Trump was a very active twitterer and had about 88 million followers.

    Many celebrities are happy with the ban, but others point to censorship. Big Tech is also accused of restricting freedom of speech. The question is whether Trump will soon take a formal approach to Big Tech.

    Today Top Movers

    Castor Maritime Inc (CTRM), a Marine Shipping company, soared about 7.49% ‎at $0.21 in pre-market trading Monday following the declaration of pricing of $26.0 million registered direct offering. 

    ‎Nio Inc (NIO) share price jumped 6.26% to $62.61 during the early morning ‎trading session on Monday. 

    ‎Sundial Growers Inc (SNDL) stock ascended 15.66% at $0.79 in the pre-market trading today.

    ‎Avinger Inc (AVGR) gained over 28.40% at $1.15 in pre-market ‎trading on Monday.‎‎

    Top Upgrades & Downgrades


    RBC Capital turned bullish on Royal Gold Inc. (RGLD), upgrading the stock to “Outperform” and assigning a $150.0 price target, representing a potential upside of 42.05% from Friday’s close. 

    Boot Barn Holdings Inc. (BOOT) has won the favor of JP Morgan’s equity research team. The firm upgraded the shares from Neutral to Overweight and moved their price target to $60.0, suggesting 23.48% additional upside for the stock. 

    Anaplan Inc. (PLAN) received an upgrade from analysts at Jefferies, who also set their one-year price target on the stock to $85.0. They changed their rating on PLAN to Buy from Hold in a recently issued research note. 

    Earlier Monday Piper Sandler reduced its rating on salesforce.com inc. (CRM) stock to Neutral from Overweight and assigned the price target to $242.0. With shares trading at around $222.04, the Wall Street firm thinks salesforce.com’s stock could add than 8.94%.
     

    Ladenburg Thalmann analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Lipocine Inc. (LPCN) has been changed to Buy from Neutral and the new price target is set at $3. 

    Analysts at BMO Capital downgraded Archer-Daniels-Midland Company (ADM)’s stock to Market Perform from Outperform on Monday.

    Latest Insider Activity

    Sunrun Inc. (RUN) Chairman Fenster Edward Harris announced the sale of shares taking place on Jan 07 at $89.10 for some 50,000 shares. The total came to more than $4.46 million. 

    Chegg Inc. (CHGG) PRESIDENT, CEO & CO-CHAIRMAN ROSENSWEIG DANIEL sold on Jan 07 a total 1,907,090 shares at $91.14 on average. The insider’s sale generated proceeds of almost $2.55 million.
     

    Hall of Fame Resort & Entertainment Company (HOFV) Director Lichter Stuart declared the purchase of shares taking place on Dec 29 at $1.40 for some 10,813,774 shares. The transaction amount was around $15.14 million. 

    Aileron Therapeutics Inc. (ALRN) Satter Muneer A bought on Jan 08 a total of 16,609,449 shares at $1.10 on average. The purchase cost the insider an estimated $9.9 million.

    Important Earnings

    Top US earnings releases scheduled for today include Simulations Plus Inc. (NASDAQ: SLP). It will announce its Nov 2020 financial results. The company is expected to report earnings of $0.11 per share from revenues of $10.64M in the three-month period. 

    Kura Sushi USA Inc. (KRUS), due to announce earnings after the market closes today, is expected to report earnings of -$0.65 per share from revenues of $8.19M recently concluded three-month period.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.

  • Top key players of Biotech Industry

    Top key players of Biotech Industry

    It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention.

    The Pfizer and BioNTech vaccine is developed on mRNA science, more straightforward, quicker, and cheaper to produce than standard vaccines. Even so, amid the enormous capital and expertise of Pfizer, the large pharmaceutical firm has failed to reach the production goals it initially set for the vaccine, needing to cut the original 100 million doses in 2020 to 50 million last month.

    The development issues are not restricted to vaccines for Covid-19 either. The FDA authorized the use of antibody drugs to treat Covid-19 last month, for example, complicated to develop. Other indications include diagnostics and cell therapies are in development. Flowing are the key performers from the Biotech sectors in yesterday’s market session.

    Xenetic Biosciences Inc. (NASDAQ:XBIO) shares were trading up 193.52% at $3.17 at the time of writing on Wednesday following declaration that it saw positive data from its partner PJSC Pharmsynthez about its pivotal Phase 3 clinical study leveraging PolyXen to develop a treatment for anemia in patients with chronic kidney disease (CKD).

    Xenetic Biosciences Inc. (NASDAQ:XBIO) share price went from a low point around $0.44 to briefly over $1.85 in past 52 weeks, though shares have since pulled back to $3.17. XBIO market cap has remained high, hitting $20.45M at the time of writing, giving it price-to-sales ratio of more than 60.

    If we look at the recent analyst rating XBIO, Maxim Group initiated coverage on XBIO shares with a Buy rating.

    Moderna Inc. (MRNA) last closed at $156.59, in a 52-week range of $17.68 to $178.50. The healthcare firm recently declared that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Analysts have a consensus price target of $122.60.

    GeoVax Labs Inc. (GOVX) stock soar by 79.06% to $5.73. The company on November 30, 2020 reported license agreement with NIH to support continued advancements in vaccine development. The most recent rating by Maxim Group, on November 19, 2020, is at a Buy.

    Intec Pharma Ltd (NASDAQ:NTEC) Shares headed rising, higher as much as 34.10% after declaring that it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.. The most recent rating by Ladenburg Thalmann, on December 09, 2020, is at a Buy.

    Atossa Therapeutics Inc. (NASDAQ:ATOS) fall -39.03% after losing more than -$0.56 on Wednesday after the company reported pricing of $20.0 million underwritten public offering.

    Sorrento Therapeutics Inc. (SRNE) last closed at $8.21, in a 52-week range of $1.55 to $19.39. The company reported that it received US FDA clearance to proceed with Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in healthy volunteers and in newly diagnosed COVID-19 Patients.

    Greenwich LifeSciences Inc. (GLSI) stock soar by 998.35% to $57.10 after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.

    Jaguar Health Inc. (NASDAQ:JAGX) Shares headed falling, lower as much as -11.45%. The most recent rating by Rodman & Renshaw, on July 11, 2017, is at a Buy.

    Lipocine Inc. (NASDAQ:LPCN) fall -21.43% after losing more than -$0.36 on Wednesday following the announcement from the company that the U.S. Food and Drug Administration has granted tentative approval to TLANDO

    Tonix Pharmaceuticals Holding Corp. (TNXP) last closed at $0.64, in a 52-week range of $0.39 to $2.46. On December 3, 2020, the firm declared positive phase 3 RELIEF study results for TNX-102 SL 5.6 mg in Fibromyalgia.

    SELLAS Life Sciences Group Inc. (SLS) stock soar by 73.17% to $6.39. The company on December 7, 2020 revealed an exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China. The most recent rating by Oppenheimer, on November 01, 2018, is at an Outperform.

    AIkido Pharma Inc. (NASDAQ:AIKI) Shares headed rising, higher as much as 4.07% after declaring the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.

    Celsion Corporation (NASDAQ:CLSN) rose 12.90% after gaining more than $0.08 on Wednesday.

    ADMA Biologics Inc. (ADMA) last closed at $2.22, in a 52-week range of $1.45 to $4.65. The firm recently announced $100 million credit facility loan amendment with perceptive advisors.

    Onconova Therapeutics Inc. (ONTX) stock soar by 1.75% to $0.32. On November 23, 2020, the company reported the filing of an investigational new drug application for Multi-kinase CDK4/6 Inhibitor ON 123300. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.

  • Is this the news why Lipocine Inc. (NASDAQ: LPCN) shares took a hike in the After-hours?

    Is this the news why Lipocine Inc. (NASDAQ: LPCN) shares took a hike in the After-hours?

    Lipocine Inc. (NASDAQ: LPCN), shares jumped 22.62% in the after-hours after the announcement by the clinical-stage biotech firm focusing on metabolic and endocrine diseases, recently confirmed that the U.S. TLANDO, the oral testosterone medication for testosterone replacement therapy in adult males, has been tentatively approved by the Food and Drug Administration for disorders associated with lack or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

    In granting preliminary approval, the FDA determined that TLANDO meets all the consistency, protection, and effectiveness requirements needed for approval, but that TLANDO did not obtain final approval and that it is not available for final approval and marketing in the United States until the expiry of the exclusivity term previously given to Clarus Therapeutics, Inc. in respect of Jatenzo, which expires in March.

    Lipocine is actively evaluating the preliminary approval of TLANDO by the FDA and remains committed to taking adequate steps to gain full approval to allow TLANDO to be released. The FDA has also required Lipocine to perform some post-marketing trials to assess patient awareness of the critical risks associated with TLANDO and (ii) evaluate adrenal insufficiency production with chronic TLANDO treatment.